Literature DB >> 25722366

Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis.

Natalie Kappus1, Bianca Weinstock-Guttman2, Jesper Hagemeier1, Cheryl Kennedy1, Rebecca Melia1, Ellen Carl1, Deepa P Ramasamy1, Mariya Cherneva1, Jacqueline Durfee1, Niels Bergsland3, Michael G Dwyer1, Channa Kolb2, David Hojnacki2, Murali Ramanathan4, Robert Zivadinov5.   

Abstract

BACKGROUND: Cardiovascular (CV) risk factors have been associated with changes in clinical outcomes in patients with multiple sclerosis (MS).
OBJECTIVES: To investigate the frequency of CV risks in patients with MS and their association with MRI outcomes.
METHODS: In a prospective study, 326 patients with relapsing-remitting MS and 163 patients with progressive MS, 61 patients with clinically isolated syndrome (CIS) and 175 healthy controls (HCs) were screened for CV risks and scanned on a 3T MRI scanner. Examined CV risks included hypertension, heart disease, smoking, overweight/obesity and type 1 diabetes. MRI measures assessed lesion volumes (LVs) and brain atrophy. Association between individual or multiple CV risks and MRI outcomes was examined adjusting for age, sex, race, disease duration and treatment status.
RESULTS: Patients with MS showed increased frequency of smoking (51.7% vs 36.5%, p = 0.001) and hypertension (33.9% vs 24.7%, p=0.035) compared with HCs. In total, 49.9% of patients with MS and 36% of HCs showed ≥ 2 CV risks (p = 0.003), while the frequency of ≥ 3 CV risks was 18.8% in the MS group and 8.6% in the HCs group (p = 0.002). In patients with MS, hypertension and heart disease were associated with decreased grey matter (GM) and cortical volumes (p < 0.05), while overweight/obesity was associated with increased T1-LV (p < 0.39) and smoking with decreased whole brain volume (p = 0.049). Increased lateral ventricle volume was associated with heart disease (p = 0.029) in CIS.
CONCLUSIONS: Patients with MS with one or more CV risks showed increased lesion burden and more advanced brain atrophy. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  MULTIPLE SCLEROSIS

Mesh:

Year:  2015        PMID: 25722366     DOI: 10.1136/jnnp-2014-310051

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  44 in total

1.  Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients.

Authors:  Dejan Jakimovski; Ralph Hb Benedict; Karen Marr; Sirin Gandhi; Niels Bergsland; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Mult Scler       Date:  2019-01-09       Impact factor: 6.312

Review 2.  Beyond rehabilitation: A prevention model of reserve and brain maintenance in multiple sclerosis.

Authors:  Rachel Brandstadter; Ilana Katz Sand; James F Sumowski
Journal:  Mult Scler       Date:  2019-09       Impact factor: 6.312

Review 3.  How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage?

Authors:  Maximilien Baron; Philippe Grise; Jean-Nicolas Cornu
Journal:  World J Nephrol       Date:  2016-03-06

4.  Neck Vessel Cross-Sectional Area Measured with MRI: Scan-Rescan Reproducibility for Longitudinal Evaluations.

Authors:  Laura Pelizzari; Maria Marcella Laganà; Dejan Jakimovski; Niels Bergsland; Jesper Hagemeier; Giuseppe Baselli; Robert Zivadinov
Journal:  J Neuroimaging       Date:  2017-12-04       Impact factor: 2.486

Review 5.  Brain MRI atrophy quantification in MS: From methods to clinical application.

Authors:  Maria A Rocca; Marco Battaglini; Ralph H B Benedict; Nicola De Stefano; Jeroen J G Geurts; Roland G Henry; Mark A Horsfield; Mark Jenkinson; Elisabetta Pagani; Massimo Filippi
Journal:  Neurology       Date:  2016-12-16       Impact factor: 9.910

Review 6.  The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Authors:  Ruth Geraldes; Olga Ciccarelli; Frederik Barkhof; Nicola De Stefano; Christian Enzinger; Massimo Filippi; Monika Hofer; Friedemann Paul; Paolo Preziosa; Alex Rovira; Gabriele C DeLuca; Ludwig Kappos; Tarek Yousry; Franz Fazekas; Jette Frederiksen; Claudio Gasperini; Jaume Sastre-Garriga; Nikos Evangelou; Jacqueline Palace
Journal:  Nat Rev Neurol       Date:  2018-03-09       Impact factor: 42.937

7.  White matter tract network disruption explains reduced conscientiousness in multiple sclerosis.

Authors:  Tom A Fuchs; Michael G Dwyer; Amy Kuceyeski; Sanjeevani Choudhery; Keith Carolus; Xian Li; Matthew Mallory; Bianca Weinstock-Guttman; Dejan Jakimovski; Deepa Ramasamy; Robert Zivadinov; Ralph H B Benedict
Journal:  Hum Brain Mapp       Date:  2018-05-08       Impact factor: 5.038

Review 8.  Wellness and the Role of Comorbidities in Multiple Sclerosis.

Authors:  Brandon P Moss; Mary R Rensel; Carrie M Hersh
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

9.  Cardiovascular profile improvement during Natalizumab treatment.

Authors:  Marcello Moccia; Roberto Albero; Roberta Lanzillo; Francesco Saccà; Anna De Rosa; Cinzia Valeria Russo; Antonio Carotenuto; Raffaele Palladino; Vincenzo Brescia Morra
Journal:  Metab Brain Dis       Date:  2017-12-18       Impact factor: 3.584

10.  Lower Arterial Cross-Sectional Area of Carotid and Vertebral Arteries and Higher Frequency of Secondary Neck Vessels Are Associated with Multiple Sclerosis.

Authors:  P Belov; D Jakimovski; J Krawiecki; C Magnano; J Hagemeier; L Pelizzari; B Weinstock-Guttman; R Zivadinov
Journal:  AJNR Am J Neuroradiol       Date:  2017-12-07       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.